Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Variants & evidence
841 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL2 W469C1 | ||||||||
| Dasatinib + ImatinibSubstitutes | Lung Adenocarcinoma | Predictive | D | Does Not Support Sensitivity Response | 3 | accepted | EID10077Four lung adenocarcinoma cell lines were studied with mutations in ABL1 or ABL2. Sensitivity to imatinib or dasatinib treatment was measured by reduction in colony formation in response to treatment. … (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC | civic |
| ABL2 Y399C1 | ||||||||
| Dasatinib + ImatinibSubstitutes | Lung Adenocarcinoma | Predictive | D | Does Not Support Sensitivity Response | 3 | rejected | EID10078Four lung adenocarcinoma cell lines were studied with mutations in ABL1 or ABL2. Sensitivity to imatinib or dasatinib treatment was measured by reduction in colony formation in response to treatment. … (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC | civic |
| ACTA1 EXPRESSION1 | ||||||||
| (prognostic) | Lung Adenocarcinoma | Prognostic | B | Supports Poor Outcome | 2 | accepted | EID1161ActA level was measured in serum and plasma samples of 64/87 lung adenocarcinoma patients and 46/66 age- and gender-matched controls (ELISA). ActA Levels were higher in patients than in controls and w… (full text at CIViC) PMID 26950277 · Hoda et al., 2016 · Open in CIViC | civic |
| ACTL6A Overexpression2 | ||||||||
| Cisplatin | Lung Adenocarcinoma | Predictive | D | Supports Resistance | 4 | submitted | EID8977High expression of ACTL6A has been shown to be associated with resistance to cisplatin in multiple cancer types. In vitro experiments using A549 and H1299 lung cancer cell lines showed that overexpres… (full text at CIViC) PMID 33408251 · Xiao et al., 2021 · Open in CIViC | civic |
| Cisplatin + PanobinostatCombination | Lung Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID8978ACTL6A plays a role in DNA damage repair by maintaining integrity of the SWI/SNF complex, and is associated with resistance to cisplatin. Results from cell viability and survival assays showed that tr… (full text at CIViC) PMID 33408251 · Xiao et al., 2021 · Open in CIViC | civic |
| BRAF Fusion1 | ||||||||
| (diagnostic) | Thyroid Gland Papillary CarcinomaALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID462The AKAP9-BRAF fusion gene was found in 3/28 tumor samples of radiation-associated papillary thyroid carcinoma, and no samples of non-radiation associated papillary thyroid carcinoma. This fusion was … (full text at CIViC) PMID 15630448 · Ciampi et al., 2005 · Open in CIViC | civic |
| AKT2 Amplification1 | ||||||||
| Everolimus + VandetanibCombination | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID1621Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion… (full text at CIViC) PMID 25982012 · Subbiah et al., 2015 · Open in CIViC | civic |
| AKT3 Overexpression1 | ||||||||
| Pan-AKT Kinase Inhibitor GSK690693 | Triple-Negative Breast CarcinomaALIAS | Predictive | E | Supports Sensitivity Response | 4 | accepted | EID1923AKT3 was found to be preferentially required for the proliferation and tumor growth of TNBC. It was found to be upregulated in a set of TNBC cell lines compared to other breast cancer types. Depletion… (full text at CIViC) PMID 24335962 · Chin et al., 2014 · Open in CIViC | civic |
| ALK G1202R + ALK Fusion1 | ||||||||
| Crizotinib | Lung Adenocarcinoma | Predictive | C | Supports Resistance | 3 | accepted | EID1357A patient with ALK-rearranged lung adenocarcinoma responded to crizotinib treatment and then had relapse. Biopsy was taken within half a month and total DNA was extracted from the sample. Exons 20-28,… (full text at CIViC) PMID 22277784 · Katayama et al., 2012 · Open in CIViC | civic |
| ALK G881D + ALK S413N + ALK V597A + ALK Y1239H1 | ||||||||
| (oncogenic) | Lung Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 2 | submitted | EID13125Analysis of 48 lung adenocarcinomas identified novel ALK mutations in six tumours, including S413N in the MAM1 domain, V597A in the MAM2, H694R in an undefined region, G881D in the glycine-rich domain… (full text at CIViC) PMID 21847362 · Wang et al., 2011 · Open in CIViC | civic |
| ALK E1384K + ALK H694R1 | ||||||||
| (oncogenic) | Lung Adenocarcinoma | Oncogenic | D | Supports Oncogenicity | 4 | submitted | EID13124Analysis of 48 lung adenocarcinomas identified novel ALK mutations in six tumours, including S413N in the MAM1 domain, V597A in the MAM2, H694R in an undefined region, G881D in the glycine-rich domain… (full text at CIViC) PMID 21847362 · Wang et al., 2011 · Open in CIViC | civic |
| NRG1 Fusion + KRAS WildtypeNRG1KRAS1 | ||||||||
| Afatinib | Pancreatic Ductal Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7493Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. In a 54-year-old … (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC | civic |
| ARID1A Loss1 | ||||||||
| (oncogenic) | Ovarian Clear Cell Adenocarcinoma | Oncogenic | B | Supports Oncogenicity | 4 | submitted | EID13135Ovarian clear cell carcinoma is a relatively chemotherapy-refractory ovarian cancer subtype with a comparatively stable genome and a well-recognized association with endometriosis, but the somatic alt… (full text at CIViC) PMID 20942669 · Wiegand et al., 2010 · Open in CIViC | civic |
| ARID1A Underexpression1 | ||||||||
| (prognostic) | Clear Cell Renal Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID5676This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed. These samples were then divided according to ARID1A expression after immunohis… (full text at CIViC) PMID 25628030 · Park et al., 2015 · Open in CIViC | civic |
| ARID2 R1273* (c.3817C>T)1 | ||||||||
| (predisposing) | Hepatocellular Carcinoma | Predisposing | D | Supports Predisposition | 3 | submitted | EID8051Mutation of ARID2 in Hepatocellular Carcinoma (HCC) is often seen. There is about 6/16 of the truncated mutations found at the C2H2 domain (zinc finger) and about 16/24 mutations show that this domain… (full text at CIViC) PMID 32071245 · Jiang et al., 2020 · Open in CIViC | civic |
| TFE3 Fusion2 | ||||||||
| (diagnostic) | Renal Cell Carcinoma with MiT Translocations | Diagnostic | B | Supports Positive | 3 | rejected | EID11529Argani, et al. (2001) included eight morphologically distinctive renal cell carcinomas with the t(X;17) translocation as seen in alveolar soft part sarcoma (ASPS), with the distinction that the t(X;17… (full text at CIViC) PMID 28766250 · Ju et al., 2018 · Open in CIViC | civic |
| 〃 | Renal Cell Carcinoma with MiT Translocations | Diagnostic | B | Supports Positive | 3 | accepted | EID11532Argani, et al. (2001) included eight morphologically distinctive renal cell carcinomas with the t(X;17) translocation as seen in alveolar soft part sarcoma (ASPS), with the distinction that the t(X;17… (full text at CIViC) PMID 11438465 · Argani et al., 2001 · Open in CIViC | civic |
| ATM Loss-of-function1 | ||||||||
| Olaparib | Lung Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID5995Bi-allelic Atm deletion in mouse models of Kras-mutant lung adenocarcinoma does not affect cisplatin responses. In marked contrast, Atm-deficient tumors displayed an enhanced response to the topoisome… (full text at CIViC) PMID 28363999 · Schmitt et al., 2017 · Open in CIViC | civic |
| ATM R2034Ter1 | ||||||||
| Olaparib | Pancreatic Ductal Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 1 | submitted | EID13230A 77 year old man with metastatic pancreatic ductal adenocarcinoma with somatic ATM R2034Ter mutation received off label olaparib after prior chemotherap. His disease remained stable for 18 months. PMID 40273902 · Vornhülz et al., 2025 · Open in CIViC | civic |
| ATM Underexpression1 | ||||||||
| Olaparib | Gastric Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID878Low ATM protein expression led to sensitivity to PARP inhibitors in TP53 -ve gastric cancer cell lines (8 lines were used for various aspects of this study). PMID 24841718 · Kubota et al., 2014 · Open in CIViC | civic |
| NRG1 Fusion + KRAS WildtypeNRG1KRAS1 | ||||||||
| Afatinib | Pancreatic Ductal Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7492Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. A 59-year-old met… (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC | civic |
| AURKA Amplification1 | ||||||||
| Alisertib + CisplatinCombination | Esophageal AdenocarcinomaALIAS | Predictive | E | Supports Sensitivity Response | 3 | accepted | EID456Antitumour effect of alisertib treatment in esophageal adenocarcinomas can be intensified in combination with cisplatin. PMID 22302096 · Sehdev et al., 2012 · Open in CIViC | civic |
| AURKA Overexpression3 | ||||||||
| Alisertib + CisplatinCombination | Esophageal AdenocarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID9627The efficacy of novel AURKA inhibitor alisertib (MLN8327) was tested alone or in combination with cisplatin in three esophageal adenocarcinoma cell lines (FLO-1, OE19 and OE33) that overexpress AURKA.… (full text at CIViC) PMID 22302096 · Sehdev et al., 2012 · Open in CIViC | civic |
| Paclitaxel | Cervical AdenocarcinomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID457In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol. PMID 12559175 · Anand et al., 2003 · Open in CIViC | civic |
| Platinum Compound | Ovarian Serous Adenocarcinoma | |||||||
| B4GALT1 Overexpression1 | ||||||||
| (prognostic) | Renal Cell CarcinomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1278438 patients with non-metastatic clear-cell renal carcinoma were were retrospectively analysed for B4GALT1 expression via IHC. High B4GALT1 expression was associated with poor overall survival (P<0.00… (full text at CIViC) PMID 27092876 · Xie et al., 2016 · Open in CIViC | civic |
| BAP1 Mutation4 | ||||||||
| (prognostic) | Clear Cell Renal Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 5 | accepted | EID459In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type. PMID 23797736 · Sato et al., 2013 · Open in CIViC | civic |
| 〃 | Renal Cell CarcinomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 5 | accepted | EID460In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type. PMID 23797736 · Sato et al., 2013 · Open in CIViC | civic |
| 〃 | Clear Cell Renal Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 5 | accepted | ||
| BAP1 Q267fs1 | ||||||||
| Niraparib | Clear Cell Renal Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 1 | submitted | EID11199A patient with Clear cell renal cell carcinoma previously treated with sorafenib, axitinib, and everolimus was found to harbor a BAP1 frameshift mutation described as c.799_800del (p.Q267fs). Based o… (full text at CIViC) PMID 35875073 · Lian et al., 2022 · Open in CIViC | civic |
| BARD1 G320*1 | ||||||||
| Carboplatin + GemcitabineCombination | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID13253A patient with lung adenocarcinoma harboring a somatic homozygous BARD1 G320* stop-gain alteration and an RBBP8 exon 3–4 duplication was classified as homologous recombination deficient by HRDetect an… (full text at CIViC) PMID 36964191 · Tsang et al., 2023 · Open in CIViC | civic |
| BIRC5 Overexpression1 | ||||||||
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Supports Resistance | 4 | accepted | EID144913 HER2 breast cancer patients were treated with trastuzumab and then trastuzumab + docetaxel prior to surgery. Pretreatment biopsies and post-treatment surgical samples were obtained, and microarray … (full text at CIViC) PMID 23204226 · Chakrabarty et al., 2013 · Open in CIViC | civic |
| BIRC7 Amplification1 | ||||||||
| (prognostic) | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | E | Supports Poor Outcome | 3 | submitted | EID8314The results proposes a potential that BIRC7 represses PTC cell autophagy, causing increase in the migration and mtastatic ability of these cells PMID 32064154 · Liu et al., 2020 · Open in CIViC | civic |
| CUL1 Fusion1 | ||||||||
| Mitogen-Activated Protein Kinase Kinase Inhibitor | Ovarian Serous AdenocarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1662One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcri… (full text at CIViC) PMID 26324360 · Grisham et al., 2015 · Open in CIViC | civic |
| BRAF G466V1 | ||||||||
| Pan-RAF/MEK Molecular Glue NST-628 | Lung Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID13159In the BRAF G466V-mutant NCI-H1666 model, NST-628 suppressed MAPK signaling without inducing BRAF–CRAF heterodimer formation. NCI-H1666 was also included in a panel of BRAF class II/III-mutant cell li… (full text at CIViC) PMID 38588399 · Ryan et al., 2024 · Open in CIViC | civic |
| BRAF G469A2 | ||||||||
| Osimertinib | Lung Adenocarcinoma | Predictive | D | Supports Resistance | 5 | rejected | EID10514PC9 cells harboring an in-frame deletion in exon 19 of the EGFR gene were cultured in the presence of increasing concentrations of osimertinib. Three clones resistant to osimertinib were isolated and … (full text at CIViC) PMID 31502118 · La Monica et al., 2019 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | D | Supports Resistance | 5 | rejected | EID10515PC9 cells harboring an in-frame deletion in exon 19 of the EGFR gene were cultured in the presence of increasing concentrations of osimertinib. Three clones resistant to osimertinib were isolated and … (full text at CIViC) PMID 31502118 · La Monica et al., 2019 · Open in CIViC | civic |
| BRAF G469E1 | ||||||||
| Trametinib | Breast Ductal Carcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID7861Subprotocol R of the NCI-MATCH study tested the MEK inhibitor trametinib in non-V600 BRAF mutant tumors. 32 patients were eligible and received therapy with trametinib. Of these 1 patient had a confir… (full text at CIViC) PMID 31924734 · Johnson et al., 2020 · Open in CIViC | civic |
| BRAF G596V1 | ||||||||
| Vemurafenib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4779In a retrospective study of 35 lung adenocarcinoma patients (chemotherapy previously administered in 86% of patients), a patient harboring a BRAF G596V mutation was associated with partial response to… (full text at CIViC) PMID 26200454 · Gautschi et al., 2015 · Open in CIViC | civic |
| BRAF Kinase Domain Duplication1 | ||||||||
| Regorafenib | Acinar Cell CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 4 | submitted | EID12470A 30 year old women with advanced acinic cell tumor of the right parotid gland had her disease progressed after initial systemic chemotherapy, followed by empirical erlotinib hydrochloride therapy. Pr… (full text at CIViC) PMID 26562024 · Klempner et al., 2016 · Open in CIViC | civic |
| BRAF V600E9 | ||||||||
| (diagnostic) | Thyroid Gland Papillary CarcinomaALIAS | Diagnostic | B | Supports Positive | 5 | accepted | EID80Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer. PMID 24570209 · Crescenzi et al., 2014 · Open in CIViC | civic |
| (prognostic) | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | B | Does Not Support Poor Outcome | 5 | accepted | EID102Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer. PMID 24354346 · Walczyk et al., 2014 · Open in CIViC | civic |
| 〃 | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | B | Supports | ||||
Data updated 21 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| Predictive |
| B |
| Supports Resistance |
| 3 |
| accepted |
EID1650A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P = 0.001; HR 0.14) and platinum therapy resistance … (full text at CIViC) PMID 27209210 · Mignogna et al., 2016 · Open in CIViC |
| civic |
EID461In patients with clear cell renal cell carcinoma, those with nonsilent mutations of BAP1 had worse overall survival than wild-type. PMID 23792563 · 2013, Nature · Open in CIViC |
| civic |
| Everolimus + SunitinibSequential | Clear Cell Renal Cell Carcinoma | Predictive | B | Supports Resistance | 4 | accepted | EID5339This study evaluated the effects of everolimus and sunitinib on patients with metastatic renal cell carcinoma. A total of 220 patients with RCC were evaluated for 341 genes at 540x coverage. Of all 22… (full text at CIViC) PMID 27751729 · Hsieh et al., 2017 · Open in CIViC | civic |
| 5 |
| accepted |
EID656In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T (N=35), recurrence-free survival is worse than in patients harboring one of these mutations (N=… (full text at CIViC) PMID 25024077 · Xing et al., 2014 · Open in CIViC |
| civic |
| 〃 | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID2137In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC) PMID 18682506 · Elisei et al., 2008 · Open in CIViC | civic |
| 〃 | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID9170Clinical study including 219 patients with papillary thyroid cancer (PTC) to determine a correlation between the BRAF V600E mutation and poor oncological outcome. This study found that 107 of the 219 … (full text at CIViC) PMID 16174717 · Xing et al., 2005 · Open in CIViC | civic |
| 〃 | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID105BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts. PMID 21594703 · Howell et al., 2011 · Open in CIViC | civic |
| 〃 | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID106BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases. PMID 24396464 · He et al., 2014 · Open in CIViC | civic |
| 〃 | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID107V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo). PMID 21594703 · Howell et al., 2011 · Open in CIViC | civic |
| 〃 | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID2503In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC) PMID 21882184 · Kim et al., 2012 · Open in CIViC | civic |